Authors: Hiroji Iwata Masaru Narabayashi Yoshinori Ito Shigehira Saji Yasuhiro Fujiwara Shigeyuki Usami Koichi Katsura Yasutsuna Sasaki
Publish Date: 2012/07/19
Volume: 18, Issue: 4, Pages: 621-628
Abstract
It is known that one third of patients with human epidermal growth factor receptor 2 HER2overexpressing metastatic breast cancer MBC treated with trastuzumab will develop brain metastases As the development of brain metastases is fatal controlling its progression is clinically meaningful However effective therapy for MBC patients with brain metastasis after cranial radiation is limited The international clinical study in which six Japanese patients participated indicated the antitumor activity of lapatinib against brain metastases of HER2overexpressing breast cancerOf six Japanese patients treated in this study two patients had shown volumetric reduction 20 in their central nervous system CNS one of whom had 50 reduction Three patients including two of these patients had shown 20 volumetric reduction in nonCNS lesions Frequently reported adverse events were diarrhea and rash all of which were controllable The AUC0–12 of lapatinib on day 28 was 174 times higher than that on day 1These results suggest that lapatinib monotherapy 750 mg given twice daily can exert some efficacy and has potential as a clinically meaningful treatment option for Japanese HER2overexpressing breast cancer patients with brain metastases after cranial radiation
Keywords: